Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 3/2004

01-06-2004 | ORIGINAL ARTICLE

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck

Authors: Mamoru Tsukuda, Yasukazu Mikami, Yuji Tanigaki, Hideaki Katori, Choichi Horiuchi, Yoichi Ikeda, Takahide Taguchi, Machiko Ono, Takahumi Yoshida, Yasunori Sakuma, Ken Aikoh

Published in: International Journal of Clinical Oncology | Issue 3/2004

Login to get access
Metadata
Title
Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck
Authors
Mamoru Tsukuda
Yasukazu Mikami
Yuji Tanigaki
Hideaki Katori
Choichi Horiuchi
Yoichi Ikeda
Takahide Taguchi
Machiko Ono
Takahumi Yoshida
Yasunori Sakuma
Ken Aikoh
Publication date
01-06-2004
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 3/2004
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-004-0390-8

Other articles of this Issue 3/2004

International Journal of Clinical Oncology 3/2004 Go to the issue

CASE REPORT

Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer

ORIGINAL ARTICLE

Alternate-day oral therapy with TS-1 for advanced gastric cancer

CASE REPORT

Advanced pancreatic carcinoma showing a complete response to arterial infusion chemotherapy

LETTER TO THE EDITOR

A young woman with clear cell adenocarcinoma of the uterine cervix

ORIGINAL ARTICLE

Surgical resection deteriorates gemcitabine-induced leukopenia in pancreatic cancer

ORIGINAL ARTICLE

Erythropoietin/Erythropoietin-receptor system as an angiogenic factor in chemically induced murine hepatic tumors
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits